BioMérieux acquires Specific Diagnostics

Create PDF

“By combining the advanced technology of the Specific Reveal Rapid AST solution for bloodstream infections with our existing solutions, we are increasing the ability of laboratories to deliver results in record time, especially in cases of very critical infections such as sepsis, which require urgent and appropriate treatment,” Mark Miller, executive vice president and chief medical officer of BioMérieux, said in a press statement.

The deal is expected to close by the end of the second quarter of this year.